*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Callan JMB Inc. (NASDAQ: CJMB)
CJMB is our brand new NASDAQ high growth alert.
This is a hidden gem opportunity that not many have seen and we are among the first to bring it to your attention.
The chart setup is pointing to a potential breakout opportunity and momentum can build very quickly.
CJMB has a history of experiencing high volatility & the company announced multiple big accomplishments recently.
CJMB is a NASDAQ listed “diversified company focused on logistics, emergency preparedness and critical infrastructure”.
CJMB is an “integrated logistics and infrastructure services company supporting the healthcare industry, emergency-management agencies, and other organizations responsible for maintaining essential operations”.
CJMB provides “fulfillment, specialty packaging, warehousing, cold-chain logistics, monitoring, regulatory compliance, inventory management, and emergency-preparedness and response services.”
The company’s mission is to “Deliver reliability to our customers by anticipating, responding, and overcoming the most complex situations with precision and compassion.”
CJMB's foundation is a business that “Prioritizes the safety and integrity of every medical countermeasure handled, ensuring effective responses to public health emergencies.”
CJMB has become the “Trusted leader in anticipating and overcoming the most complex situations with precision and compassion, providing peace of mind and a comprehensive solution for our customers”.
Specialized temperature-controlled shippers are crucial for time-sensitive industries such as health care.
Track each package to ensure delivery with the efficacy of the product intact, reducing product loss and maximizing efficiency.
Thermal shippers are a sustainable reusable alternative to traditional single use packaging.
Industry demand for preparedness infrastructure and specialized cold chain support services continues to expand as municipalities, healthcare systems, government agencies, and regulated industries modernize continuity planning and emergency response capabilities.
Increasing regulatory complexity, temperature-sensitive assets, and the need for rapid deployment logistics have accelerated reliance on specialized third-party infrastructure partners capable of supporting scalable, compliant, and resilient operations.
Furthermore, only approximately 10% of active pharmaceutical ingredients (APIs) used in U.S. prescription drugs are currently produced domestically, underscoring the country's reliance on foreign manufacturing.
Over 50% of pharmaceuticals and 80% of generic drugs are currently imported, creating significant shortages and US security risk.
Furthermore, onshoring of critical active pharmaceutical ingredients (APIs) has accelerated in line with White House’s Strategic APIs Reserve (SAPIR).
Federal policy priorities, including calls to strengthen domestic pharmaceutical production and reduce reliance on foreign supply chains, demonstrate the need for scalable U.S.-based infrastructure..
CJMB will “manage logistics and operations in the U.S. for companies from India and South Korea that want to establish API manufacturing plants and distribution warehouses.”
“Secured strategic partnership with Revival Health (South Korea) and launched Callan JMB Services (India).”
“Revenue streams include logistics management fees, regulatory consulting services, and distribution partnerships.”
“Fee-for-service business model with recurring monthly management contracts, providing visibility on revenues while maintaining asset-light approach.”
Furthermore, CJMB “to provide manufacturing oversight, federal deployment coordination, quality assurance, and commercialization support for Attune’s multi-asset therapeutic pipeline.”
“Enables Attune’s pipeline for immediate federal deployment readiness by leveraging Callan JMB's existing government infrastructure, federal contract experience, cold chain infrastructure, and strategic national stockpile relationships.”
As the company explains:
“Approximate potential revenue opportunity of $25 million to $45 million for Callan JMB over the next 5 years, driven by opportunities across both federal and commercial markets.”
A real-world example of the scale involved, from the company's City of Chicago case study:
The City of Chicago awarded CJMB two separate contracts:
“7-year Pallet Storage Contract ($6M - $15M value); and
7-year Supervisory Control Data Acquisition Contract ($17M - $27M value)”
Storage of “1453 Pallets of Medical Countermeasures” and Office of Emergency Management & Communications storage of “1204 Pallets of Medical Countermeasures”
Maintenance of:
“6 Mobile hospitals
5 Stationary Generators
6 Mobile Generators
150 Ventilators
25 Radiation Portals
15 Medical Freezers/Refrigerators
700 Powered Air Purifying Respirators”
In addition, through Callan Power LLC, CJMB is “extending its experience in critical supply chains and infrastructure into energy resilience, grid reliability, and the domestic manufacturing of critical electrical equipment.”
The company has announced multiple accomplishments recently.
In April, the company announced:
“Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure”
Highlights:
“Completion of a Partnership Agreement with Walker's Pharmaceuticals of India Establishes First On-Site International Partner”
“Infrastructure Platform in Marion Positioned to Support National Pharmaceutical Resilience, Address US Security Concerns and Drive Economic Growth in Alabama”
Here are some of the company’s comments from this press release:
"Atlas Complex positions Callan JMB at the center of pharmaceutical onshoring and domestic supply chain expansion," said Wayne Williams, CEO of Callan JMB. "We are developing a top of the line, scalable campus that enables global companies to establish U.S.-based operations more efficiently, while capturing multiple long-term revenue streams aligned with important national supply chain priorities. This facility will allow large multi-national companies to reach their US government mandated onshoring goals, and provide a template for future Callan JMB projects."
In May, the company announced:
“Callan JMB Expands Long-Standing Public Sector Infrastructure Engagement”
“Strategic extension reinforces recurring revenue visibility and growing demand for preparedness, continuity, and cold chain infrastructure”
Here are some of the comments from this press release:
"Across the country, organizations are recognizing that preparedness, continuity planning, and cold chain resilience are no longer optional infrastructure components — they are mission-critical," said Wayne Williams, President & CEO of Callan JMB. "We believe demand for specialized operational support will continue growing as agencies and institutions modernize how they manage emergency readiness, regulated logistics, and infrastructure continuity."
In June, the company announced:
“Callan JMB Expands Oregon Public Health Support Capabilities Through State VFC Authorization”
“Approval enhances the Company's ability to receive, prepare, and deploy pediatric-focused medical materials in support of state and local public health initiatives”
CJMB announced that it has “received a Vaccines for Children (VFC) Program PIN authorization from the State of Oregon, expanding the Company's ability to support public health programs through the storage, management, preparation, and distribution of pediatric vaccines and other temperature-sensitive medical materials.”
Importantly:
“The authorization allows Callan JMB to participate in programs that require specialized cold chain management, regulatory compliance, inventory accountability, and the deployment of critical pediatric medical products.”
“The approval strengthens the Company's ability to support both routine public health operations and targeted response efforts by providing state and local agencies with an efficient mechanism to receive and distribute medical materials where they are needed most.”
Here are some of the company’s comments from this press release:
"This authorization expands our ability to support Oregon's public health objectives by providing additional infrastructure, cold chain capabilities, and operational support for pediatric vaccines and other critical medical materials," said Scott Bullard, COO of Callan JMB. "For public health agencies, pinpoint logistical tools are important levers for moving from planning to execution, particularly when medical materials must be deployed quickly, compliantly, and in targeted quantities. This authorization strengthens our ability to help bridge that gap by providing an efficient operational resource that supports both routine public health initiatives and targeted response efforts. As agencies continue to focus on access, readiness, and supply chain reliability, organizations that can combine regulatory compliance with practical operational execution will play an increasingly important role in supporting community health outcomes."
In July, the company announced:
“Callan JMB Inc. and Alabama State University Partner to Advance Workforce Development, Research, and Pharmaceutical Innovation at the Atlas Complex”
“Strategic partnership integrates higher education, industry, and workforce development to accelerate pharmaceutical onshoring and strengthen domestic supply chains”
Here are some of the comments from this press release:
"Atlas Complex was always envisioned as much more than a collection of buildings," said Wayne Williams, Chief Executive Officer of Callan JMB. "Our vision is to create an ecosystem where industry, higher education, innovation, and workforce development work together to solve some of the country's most important healthcare supply chain challenges. Alabama State University is an exceptional partner in helping us build that future. Together, we're creating an environment that supports innovation, develops talent, attracts investment, and strengthens America's domestic pharmaceutical capabilities."
In addition:
"Our partnership with Callan JMB began during the unprecedented challenges of the COVID-19 pandemic. What started as a collaboration focused on protecting the health and safety of our students has grown into a trusted, long-standing partnership built on a shared commitment to the success of Alabama State University and providing the very best for our students. As a university committed to preparing students to lead, innovate, and serve, Alabama State University is proud to partner with Callan JMB on an initiative that connects education directly with industry," said Dr. Quinton T. Ross Jr., President of Alabama State University. "This collaboration provides our students and faculty with meaningful opportunities to participate in applied research, workforce development, and industry engagement while contributing to the continued growth of Alabama's life sciences and advanced manufacturing sectors."
In addition, the company also announced:
“Callan JMB and Alabama State University Announce Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resilience”
“Management believes the initiative could represent a potential $414 million five-year revenue opportunity for Callan JMB while helping establish a next-generation pharmaceutical manufacturing ecosystem in the United States.”
As the company further explains:
“Under the partnership, Callan JMB would provide the operational infrastructure supporting future pharmaceutical manufacturing activities, including logistics, regulatory compliance, warehousing, facility leasing, supply chain management, housing support, and related operational services. Under the terms of the agreement, Callan JMB would receive 21% of the gross revenue generated by qualifying pharmaceutical manufacturing operations.”
On July 29, the company announced:
“Callan JMB and Alabama State University Break Ground on Atlas Complex, Launching an Unprecedented Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resilience”
Here are the highlights from this press release:
“This new landmark project is forecast to ultimately generate estimated annual gross revenues of $500 million for the partnership
Callan JMB is entitled to receive a 21% participation in the venture, which could represent approximately $105 million in revenue for the first year and over $400 million in revenues over the five-year agreement
The next phase of the project is being initiated with the development of the Marion 9 Biomanufacturing Center at the Atlas Complex by Callan JMB in Marion, Alabama”
Earlier this month, the company also announced:
“Callan JMB Expands Atlas Complex, Advances Recurring Infrastructure Services Business with Cavalry 1838 Equine Biosciences”
“Agreement reinforces the Atlas Complex strategy while expanding Callan JMB's recurring infrastructure services business through a 60% participation in enterprise revenue. The enterprise's underlying business plan contemplates annual revenue of between $12 million and $25 million within seven years under its base-case scenario.”
On August 6, the company announced:
“Callan JMB Announces Formation of Callan Power to Advance Domestic Manufacturing of Critical Electrical Infrastructure”
“Wholly owned subsidiary will initially pursue Alabama-based manufacturing of transformers and other critically needed electrical equipment”
As the company further explains:
“Callan Power will draw on more than 15 years of emergency preparedness power management experience gained through Coldchain Technology Services LLC, another wholly owned subsidiary of Callan JMB. Since 2009, Coldchain has managed fixed, hardened and mobile power-generation assets supporting healthcare organizations, government agencies and other critical operations during emergencies and planned continuity events.”
Here are some of the company’s comments:
"Callan Power is a natural extension of our preparedness mission and the experience we have developed managing fixed and mobile power resources since 2009," said Wayne Williams, President and Chief Executive Officer of Callan JMB. "By combining that operational foundation with plans to manufacture transformers and other essential electrical equipment domestically, we intend to address a critical infrastructure need while creating a meaningful new avenue for long-term growth."
In addition, most recently, the company announced:
“Callan JMB, Bia Power Systems and Alabama State University Announce $60 Million Advanced Electrical Manufacturing Venture in Brewton, Alabama”
“Planned facility is expected to support more than $150 million in annual manufacturing revenue capacity, create up to 250 jobs and advance Callan Power's domestic electrical-infrastructure strategy”
We believe CJMB could be positioned for big upside potential.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 8/20/26 for the distribution of this advertisement about CJMB dated 8/20/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.